Diarrhoea · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes adverse events: diarrhoea compared with placebo (very low certainty).
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FEV1 % predicted compared with placebo (very low certainty).
1 finding from 1 review
FVC · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes FVC % predicted compared with placebo (very low certainty).
1 finding from 1 review
Z score BMI · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: omega‐3 fatty acid supplementation changes growth and nutrition: BMI SD score compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Polyunsaturated fatty acids(5 trials; 252 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
The intervention may leads to higher polyunsaturated fatty acids(5 trials; 252 participants) (low certainty).
1 finding from 1 review
OR 4.44 [2.4, 8.48]
Studies not reported
Low
Intervention not reported
Polyunsaturated fatty acids(2 RCTs; 252 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether the intervention changes polyunsaturated fatty acids(2 RCTs; 252 participants) (very low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: Deterioration of symptoms ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: EPS: parkinsonism measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: parkinsonism measured by average ESRS change… compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: EPS: dystonia measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: dystonia measured by average ESRS change scores compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes adverse effects: EPS: akathisia measured by average ESRS change scores compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: psychotic symptoms Average total score (PANSS, higher score = worse, scale from 30‐210) Long‐term (up to 7 years) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: 1. Leaving the study early ‐ long term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in satisfaction with treatment: leaving the study early Long‐term… compared with placebo (low certainty).
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids may leads to lower prodromal symptoms: transition to psychosis Long‐term (events) compared with placebo (low certainty).
1 finding from 1 review
Global state: antipsychotic prescription Long‐term (events) · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids may leads to lower global state: antipsychotic prescription Long‐term (events) compared with placebo (low certainty).
1 finding from 1 review